CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
about
A delicate balancePurinergic signalling and cancerA Metabolic Immune Checkpoint: Adenosine in Tumor MicroenvironmentConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesCD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthEctonucleotidases in tumor cells and tumor-associated immune cells: an overviewCD73 expression is dynamically regulated in the germinal center and bone marrow plasma cells are diminished in its absenceA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentAdenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironmentNT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E proteinSpecific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage InfiltrationAutocrine adenosine signaling promotes regulatory T cell-mediated renal protection.Adenosine arrests breast cancer cell motility by A3 receptor stimulation.Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.The roles of CD73 in cancerCellular function and molecular structure of ecto-nucleotidases.NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism.Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells.Graft-versus-host disease is enhanced by selective CD73 blockade in miceAlternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice.Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologistsPullulan: a new cytoadhesive for cell-mediated cartilage repair.Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells.The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cellsCD73 Expressed on γδ T Cells Shapes Their Regulatory Effect in Experimental Autoimmune UveitisDeficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host diseaseImmune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).CD73 promotes tumor growth and metastasisHost CD73 impairs anti-tumor immunityNT5E CpG island methylation is a favourable breast cancer biomarker.Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma.Immunological mechanisms of the antitumor effects of supplemental oxygenation.Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantationA2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c(+)Gr-1(+) dendritic cell subset that promotes the Th17 response.Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
P2860
Q24615512-5BF6AF87-DBB3-4A07-87D6-F0DDD3C1C4FFQ24618782-AA5C7335-B517-450C-AA0B-38D59983FE3AQ26749571-97DB4F89-D8EF-422A-8C12-5BDE6BC92F47Q26781215-F3EFB119-492F-4A01-A9E3-3F11548CB0D7Q26823709-225DA979-97B5-4212-82F2-6D5E615673FCQ27002950-FCDC49E1-50B6-4D7A-A496-65FBD2F00C1BQ27315065-D07E06B1-1588-48EA-946B-B67FDE7B9563Q28087576-F522568B-3C58-4A6B-A2AB-FCD64C14DDF3Q28241308-43EAC606-6665-4C4E-9EA9-3AD2D813DD58Q28250207-BED03E90-4C49-4401-BB04-CF4D0692D2EBQ28539242-EA8CBE42-58AB-46A1-B59F-C53E671BB1F5Q28550667-BBC128F6-069D-4DEF-A0B6-1EC92D5EC1D7Q30417431-CB9BA681-9C39-42EE-AD20-3950C5472226Q30829844-CAEDEDB0-3845-440E-B4B2-419478F51767Q33771631-4D5A35DC-538D-43BD-9002-0A3CF0C80B9EQ34003164-B437C410-084F-4D18-855C-E1AEB05EF212Q34031794-F9BAC6D2-55FF-4A31-B8BD-7E4717B5CEECQ34123241-16F3C5AC-195E-4F78-8313-FA0117DF9D3FQ34245132-84190203-EC21-4B25-ACE5-9FAE38E5129FQ34277485-E73F8413-2441-408F-8121-425CB8533394Q34631798-23C33A05-033A-4445-B5B7-8F488A0E935DQ34680354-DD32F5B2-FC0A-44A1-9093-79D0840D29E4Q34695338-46B33CB4-CC9A-42C0-AF34-DE639EE5187BQ35090797-FDA19B5C-C00B-4468-A9AE-2F36C5A2363BQ35552862-822EAABF-1E54-433A-8A72-470AC5F522A4Q35566772-2AB5EFF2-6A7A-4A1D-90F9-8AE18A2D94B4Q35931795-BD4F1D02-D47E-438D-A2B3-DDE01126ACF6Q35937473-1035856F-2AF8-4D89-BC0C-34F5A46B3721Q35995245-798C362A-39E5-4CA9-978F-2DF95E6B32CFQ36024656-ED997752-23B6-4E44-893F-4E776C0BB6B8Q36038399-21D02677-BD2F-474F-BFED-95596A89FAA9Q36038421-AD48E621-BDDE-4FA2-A9DC-F693F94EBC71Q36075236-7972B5DF-E3B1-4606-864B-C129C61ED45CQ36233927-C059488F-3F9B-44FD-B7E3-E0AB9661275DQ36269330-170117A8-B3CF-4D38-8236-E3B7510A01DEQ36343925-D0EF30B5-0EFF-4C10-AF18-1324005D0A14Q36350059-0EC23FD8-4A5F-43E1-92BD-8B21EDA3ADBCQ36410586-6848EE79-B3B2-4BD2-ACBB-2406007A54C9Q36430733-8970BD37-6299-43D5-A43B-6E0A0BFCB440Q36449290-0C25A851-C897-49AD-B8FE-34DA58C88628
P2860
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CD73-deficient mice have incre ...... nt to experimental metastasis.
@en
CD73-deficient mice have incre ...... nt to experimental metastasis.
@nl
type
label
CD73-deficient mice have incre ...... nt to experimental metastasis.
@en
CD73-deficient mice have incre ...... nt to experimental metastasis.
@nl
prefLabel
CD73-deficient mice have incre ...... nt to experimental metastasis.
@en
CD73-deficient mice have incre ...... nt to experimental metastasis.
@nl
P2093
P1433
P1476
CD73-deficient mice have incre ...... nt to experimental metastasis.
@en
P2093
Helene Duret
John Stagg
Michele W L Teng
Tim Sparwasser
Upulie Divisekera
P304
P356
10.1158/0008-5472.CAN-10-4246
P407
P577
2011-02-03T00:00:00Z